Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

NCT00620971 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Vinorelbine
DRUG: Cisplatin
DRUG: Bevacizumab
DRUG: Docetaxel
DRUG: Gemcitabine
DRUG: Bevacizumab
DRUG: Docetaxel
DRUG: Cisplatin
DRUG: Bevacizumab

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]